| Mn | Product ID |
| 2,000 | 06020101802 |
| 5,000 | 06020101806 |
| 10,000 | 06020101809 |
| 20,000 | 06020101812 |
| 40,000 | 06020101815 |
Has been registered, DMF 037263
Xiamen Sinopeg Biotech Co., Ltd. is dedicated to drug delivery systems and related medical device business, focusing on the research, development, production and sales of high-end drug delivery carriers/auxiliary materials/APIs, medical materials, including but not limited to polyethylene glycol derivatives, lipid products, blood sugar control drug modifiers, block copolymers, ADC/ProTAC linkers, biodegradable polymers, exosomes, viral-like particles, as well as providing CDMO and solution services. These products are widely used in long-acting protein/peptide drugs, mRNA vaccines, small nucleic acid drugs, blood sugar control drugs, macromolecular micelle drugs, liposome drugs, gene therapy drugs, immunosuppressants, ADC drugs, ProTAC drugs, medical hydrogels, and other fields, placing the company in a leading position in the industry.
SINOPEG holds 40+ patents, with 80+ more pending, and 30+ products filed in DMF/CDE. The company has ISO 9001/ISO 13485/ISO 14001/ISO 45001 certification. The laboratory and production workshop are designed and built in accordance with the cGMP standard of FDA. We follow the requirements of ICH-Q7A to organize production at scale, to provide high quality drug delivery products and services to customers globally.
Our online catalog or inventory may not listed or have all molecular weights and functional groups, which may be available by custom synthesis. Please contact us at sales@sinopeg.com for quotation and availability.
Reference:
1. Pan LQ, Zhao WB, Lai J, et al. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities. Sci Rep. 2015;5:14872. Published 2015 Oct 8. doi:10.1038/srep14872
2. Wan, Xue, Xue Wan, et al. Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins. Process Biochemistry 52 (2017): 183-191. doi:10.1016/j.procbio.2016.09.029
3. Wei X, Yang X, Zhao W, Xu Y, Pan L, Chen S. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities. Bioconjug Chem. 2017;28(8):2180-2189. doi:10.1021/acs.bioconjchem.7b00327
4. Chung SF, Kim CF, Tam SY, et al. A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer. Appl Microbiol Biotechnol. 2020;104(9):3921-3934. doi:10.1007/s00253-020-10484-4
5. Pan LQ, Wang HB, Lai J, Xu YC, Zhang C, Chen SQ. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials. 2013;34(36):9115-9123. doi:10.1016/j.biomaterials.2013.08.020
